Supreme Court Highlights Overpricing of Essential Cancer Drugs and Regulatory Gaps
The Supreme Court expressed strong concern over the significant price disparity between the price to retailer (Rs 2,700) and the maximum retail price (Rs 27,000) of essential cancer medicines, calling it "broad daylight dacoity" against patients. The bench questioned the silence of regulatory authorities and highlighted the burden inflated prices place on patients and public health schemes. The court is hearing petitions seeking stricter price controls, mandatory generic prescriptions, and regulation of non-scheduled medicines, with further hearings scheduled for September 29.
First-hand measurement across 12 sources
We measured how 12 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (31/100). Lens Score 68/100.
Outlets measured: freepressjournal, hindustantimes, moneycontrol, thehindu, economictimes, indiatoday, thetribune, news18, and 4 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (25–48/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 22 Sept, 01:01 pm. Other outlets followed.